The Therapeutic Response to Alendronate in Chinese Postmenopausal Women with Osteoporosis and the AluⅠ Polymorphism of Estrogen Receptor Β Gene

汪纯,何进卫,秦跃娟,张浩,胡伟伟,刘玉娟,章振林

DOI: https://doi.org/10.3969/j.issn.1674-2591.2009.03.002

2009-01-01

Abstract:Objective To investigate whether the change of BMD after one-year alendronate treatment in post-menapausal women with osteoporosis associates with the AluⅠpolymorphism of estrogen receptorβgene(ESR2 ) and determine the correlation between genotypes and the therapeutic effect.Methods Eighty postmenopausal osteoporosis patients were recruited with the average age of(64.2±7.7) years.Every patient took oral Alendronate(Forsamax) 70mg weekly and Caltrate 600mg daily for 12 months.Pre- and post-treatment,bone mass density was measured at lumbar spine 2-4 and left hip sites.PCR-RFLP was performed for the AluⅠpolymorphism of ESR2 gene.Results One year therapy was accomplished in 67 patients.Compared with the baseline BMD,the post-treatment BMD was increased significantly at all sites.The BMD of lumbar spine 2-4 was increased(5.48±4.68)%,while the BMD of femoral neck was increased (1.77±4.72)%,the BMD of troch was increased(3.81±5.10)%,the BMD of inter-troch was increased(2.60±3.14)%and the BMD of total hip was increased(2.50±3.14)%(P0.01).In all 67 patients,no AA genotype was detected.The frequency of Aa and aa genotypes were 10.4%and 89.6%.Between Aa and aa genotypes,no significant differences of the base line BMD,the post-treatment BMD and the percentage of BMD changing were found.Conclusion The BMD of lumbar spine was increased more significantly than the BMD of hip sites in Chinese postmenopausal osteoporosis women after one-year alendronate therapy.But there is no correlation between the therapeutic response and the AluⅠpolymorphism of ESR2 gene.Larger sample studies are needed to confirm these results.